Stockscreener 앱 받기
11.03
23.63%
2.10
시간 외 거래:
11.06
0.03
+0.27%
전일 마감가:
$8.93
열려 있는:
$9.795
하루 거래량:
24.75M
Relative Volume:
6.54
시가총액:
$1.74B
수익:
$331.41M
순이익/손실:
$-226.54M
주가수익비율:
-9.3475
EPS:
-1.18
순현금흐름:
$-97.31M
1주 성능:
+32.69%
1개월 성능:
+61.64%
6개월 성능:
+56.48%
1년 성능:
+148.09%
1일 변동 폭
$9.59
$11.11
1주일 범위
$8.28
$11.11
52주 변동 폭
$4.75
$11.11
바이오크리스트 Stock (BCRX) Company Profile
명칭
Biocryst Pharmaceuticals Inc
전화
919-859-1302
주소
4505 EMPEROR BOULEVARD, DURHAM, NC
BCRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
11.03 | 1.74B | 331.41M | -226.54M | -97.31M | -1.18 |
|
ZTS
Zoetis Inc
|
158.26 | 68.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.38 | 47.71B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.62 | 46.12B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.39 | 18.55B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
298.70 | 13.40B | 2.76B | 1.11B | 898.10M | 22.77 |
바이오크리스트 Stock (BCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-02-25 | 개시 | Wedbush | Outperform |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-09-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-13 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-02-22 | 업그레이드 | Needham | Hold → Buy |
| 2022-11-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-08-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-04-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-04-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-10 | 개시 | Oppenheimer | Outperform |
| 2021-08-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2020-09-29 | 재개 | JP Morgan | Overweight |
| 2020-06-17 | 개시 | BTIG Research | Neutral |
| 2020-05-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-15 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | 재개 | Piper Jaffray | Overweight |
| 2018-08-08 | 재개 | JP Morgan | Overweight |
| 2018-07-17 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | 개시 | Seaport Global Securities | Neutral |
| 2018-01-02 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | 개시 | Barclays | Equal Weight |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-09-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-02-16 | 개시 | Ladenburg Thalmann | Buy |
| 2016-08-12 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | FBR Capital | Outperform |
| 2016-02-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2016-02-09 | 다운그레이드 | Needham | Buy → Hold |
모두보기
바이오크리스트 주식(BCRX)의 최신 뉴스
BioCryst Pharmaceuticals (BCRX) Boosts Revenue Guidance on Strong ORLADEYO Sales - GuruFocus
BioCryst: Strong Opportunity For A Double With A Proven Therapy (BCRX) - Seeking Alpha
Crude Oil Falls Over 2%; ISM Services PMI Rises In April - Benzinga
BioCryst Pharmaceuticals (BCRX) Surges on Q1 Earnings Beat: What Traders Need to Know - RagingBull
BioCryst Pharmaceuticals (BCRX) Boosts Revenue Forecast Amid Strong Q1 Results - GuruFocus
BioCryst Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:BCRX) - Seeking Alpha
BioCryst stock jumps on raised guidance, strong Q1 report - Seeking Alpha
Napco Security Technologies Posts Better-Than-Expected Results, Joins Skechers, BioCryst Pharmaceuticals And Other Big Stocks Moving Higher On Monday - Benzinga
BioCryst Hikes on Q1 Figures - Baystreet.ca
Earnings call transcript: BioCryst’s Q1 2025 revenue and stock surge - Investing.com
Earnings call transcript: BioCryst’s Q1 2025 revenue and stock surge By Investing.com - Investing.com UK
BioCryst Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
BioCryst Q1 2025 slides: ORLADEYO sales surge, guidance raised By Investing.com - Investing.com Canada
BioCryst Pharma Stock Soars 10% Pre-Market On Upbeat Q1 Earnings, Improved Full Year Guidance: Retail’s Pleased - MSN
BioCryst Pharmaceuticals (BCRX) Reports Break-Even Earnings for Q1 - Yahoo Finance
BioCryst Pharmaceuticals (BCRX) Surpasses Q1 Expectations, Raises 2025 Forecast - GuruFocus
BioCryst Reports Strong Q1 2025 Financial Performance - TipRanks
BioCryst Pharmaceuticals Inc Q1 2025 Earnings: EPS at $0.00 Beats Estimate, Revenue Surges to $145.5 Million Exceeding Expectations - GuruFocus
BioCryst (BCRX) Boosts 2025 Revenue Forecast for ORLADEYO | BCRX Stock News - GuruFocus
BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update | BCRX Stock News - GuruFocus
Earnings Flash (BCRX) BioCryst Pharmaceuticals Posts Q1 EPS $0.00, vs. FactSet Est of $0.07 Loss - marketscreener.com
BioCryst (BCRX) Reports Strong First Quarter with Revenue Surpassing Expectations | BCRX Stock News - GuruFocus
BioCryst Pharmaceuticals surges 2% on strong Q1 results, raised outlook - Investing.com Australia
BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
ARMOUR, BioCryst, Viking, Builders, Hims: Trending by Analysts - MSN
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 563 - GuruFocus
BioCryst (BCRX) Awards Restricted Stock Units to New Employees | - GuruFocus
Biocryst Reports Inducement Grants Under Nasdaq Listing Rule - marketscreener.com
BioCryst (BCRX) Awards Restricted Stock Units to New Employees | BCRX Stock News - GuruFocus
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BCRX Stock News - GuruFocus
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Attracts Top Talent with 48,000 Share RSU Package: Key Details of Latest Inducement Grants - Stock Titan
BioCryst Appoints Steve Frank to Board of Directors - GlobeNewswire
BioCryst Appoints Steve Frank to Board of Directors | BCRX Stock News - GuruFocus
BioCryst appoints J.P. Morgan executive to board - Investing.com
BioCryst appoints J.P. Morgan executive to board By Investing.com - Investing.com Nigeria
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Holdings Lowered by LPL Financial LLC - Defense World
Wells Fargo & Company MN Raises Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
Commit To Buy BioCryst Pharmaceuticals At $7, Earn 12.9% Using Options - Nasdaq
BioCryst to Present at Upcoming Investor Conferences - GlobeNewswire
BioCryst to Present at Upcoming Investor Conferences - GlobeNewswire Inc.
Cantor Fitzgerald sets BioCryst stock at Overweight, $20 target By Investing.com - Investing.com India
Cantor Fitzgerald sets BioCryst stock at Overweight, $20 target - Investing.com
BioCryst (BCRX) Coverage Initiated with Optimistic Outlook | BCR - GuruFocus
BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Citizens reiterates BioCryst stock with $18 target By Investing.com - Investing.com Canada
Citizens reiterates BioCryst stock with $18 target - Investing.com
Stocks Update From Health Care Sector -- DexCom, Alkermes, BioCryst Pharmaceuticals, Anacor Pharmaceuticals and Endologix - ADVFN
BioCryst to Report First Quarter 2025 Financial Results on May 5 - GuruFocus
BioCryst to Report First Quarter 2025 Financial Results on May 5 | BCRX Stock News - GuruFocus
바이오크리스트 (BCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.97%
0.35%
자본화:
|
볼륨(24시간):